ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma

Table 1 Characteristics of patients with hepatocelullar carcinoma receiving sorafenib treatment according to treatment outcomes

Variable	Total(n = 41)	SD + PR + CR(n = 17)	PD(n = 24)	P value
Age (yr)	74.0 (69.0-81.0)	74.0 (71.0-78.0)	74.0 (63.5-70.0)	0.400
Sex (male/female)	38/3	17/0	21/3	0.254
Etiology (HBV/HCV/NASH/alcohol)	7/20/3/11	0/13/1/3	7/7/2/8	0.0707
Albumin (g/dL)	3.6 (3.3-3.9)	3.7 (3.5-4.0)	3.5 (3.3-3.7)	0.0827
Prothrombin time (%)	82.0 (77.0-89.0)	83.0 (78.0-89.0)	82.0 (78.5-91.0)	0.751
Total bilirubin (mg/dL)	0.8 (0.6-0.9)	0.7 (0.5-0.9)	0.8 (0.6-0.9)	0.397
Platelet count (× 104/mm3)	14.1 (11.1-17.3)	16.1 (9.4-18.3)	14.1 (11.6-16.9)	0.568
AFP (ng/mL)	121.8 (11.3-2611.0)	31.8 (6.7-161.0)	286.0 (41.6-5193.5)	0.103
DCP (mAU/mL)	359.5 (58.0-5277.5)	192 (24.5-5177)	5177 (183-17214)	0.012
AFP-L3% (%)	13.2 (1.7-42.4)	12.3 (1.45-34.3)	21.8 (1.85-47.7)	0.529
VEGF (pg/mL)	25.8 (14.1-40.1)	18.5 (10.0-35.1)	28.2 (22.0-50.7)	0.106
VEGFR-2 (pg/mL)	6500 (5750-7400)	6400 (5200-7100)	6800 (6350-7600)	0.211
Maximum tumor size (cm)	3.3 (2.5-7.7)	3.2 (2.0-6.0)	4.3 (2.7-10.8)	0.220
Tumor number (1/2/3/4 or more/only distant metastasis)	3/2/1/33/2	0/2/1/13/1	3/0/0/20/1	0.131
PVTT (presence/absence)	7/34	2/15	5/19	0.679
Distant metastasis (presence/absence)	17/24	10/7	7/17	0.107
Child-pugh score	5 (5-6)	5 (5-6)	5 (5-6)	0.469
UICC TNM stage (2/3/4)	5/16/20	1/6/10	4/10/10	0.455
Observation (survival) period (d)	328 (156-530)	564 (405-880)	162 (116-319)	0.000322

Data are expressed as median (Interquartile range). P-values represent comparisons between patients with HCC who had SD+PR+CR and PD. HCC: Hepatocelullar carcinoma; HCV: Hepatitis C virus; HBV: Hepatitis B virus; NASH: Non-alcoholic steatohepatitis; AFP: Alpha fetoprotein; DCP: Des-γ-carboxy prothrombin; AFP-L3%: Lens culinaris agglutinin-reactive alpha-fetoprotein; VEGF: Vascular endothelial growth factor; VEGFR-2: VEGF receptor-2; PVTT: Portal vein tumor thrombosis; UICC: The Union for the International Cancer Control; TNM stage: Tumor-node-metastasis stage; SD: Stable disease; PR: Partial response; CR: Complete response; PD: Progressive disease.